Zogenix Inc

NASDAQ:ZGNX  
18.90
+1.37 (+7.82%)
Products, Regulatory

Zogenix Announces Positive Top-Line Results From Its Third Pivotal Phase 3 Clinical TrialOf Fintepla In Dravet Syndrome

Published: 09/10/2020 14:04 GMT
Zogenix Inc (ZGNX) - Zogenix Announces Positive Top-line Results From Its Third Pivotal Phase 3 Clinical Trial (study 3) of Fintepla® in Dravet Syndrome.
Zogenix Inc - Positive Study Will Support Japanese New Drug Application (j-nda) Submission, Planned for 2021.
Zogenix - Results Corroborate Statistically Significant Convulsive Seizure Reductions Seen in Earlier Multinational Phase 3 Studies of Fintepla in Dravet Syndrome.
Zogenix Inc - Fintepla at 0.7 Mg/kg/day Achieved a 64.8% Greater Reduction in Mean Monthly Convulsive Seizures Compared to Placebo.
Zogenix Inc - Fintepla at a Lower Dose of 0.2 Mg/kg/day Achieved a 49.9% Greater Reduction in Mean Monthly Convulsive Seizures Compared to Placebo.
Zogenix Inc - Phase 3 Study (study 3) of Fintepla Met Its Primary Objective.